AU2016202437A1 - Organic compositions to treat HSF1-related diseases - Google Patents

Organic compositions to treat HSF1-related diseases

Info

Publication number
AU2016202437A1
AU2016202437A1 AU2016202437A AU2016202437A AU2016202437A1 AU 2016202437 A1 AU2016202437 A1 AU 2016202437A1 AU 2016202437 A AU2016202437 A AU 2016202437A AU 2016202437 A AU2016202437 A AU 2016202437A AU 2016202437 A1 AU2016202437 A1 AU 2016202437A1
Authority
AU
Australia
Prior art keywords
related diseases
organic compositions
hsf1
treat
treat hsf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2016202437A
Other versions
AU2016202437B2 (en
Inventor
Jinyun CHEN
Kalyani GAMPA
Dieter Huesken
Frank P. Stegmeier
Mark Stump
Chandra Vargeese
Jan Weiler
Wenlai Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Pharmaceuticals Inc
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Priority to AU2016202437A priority Critical patent/AU2016202437B2/en
Priority claimed from AU2016202437A external-priority patent/AU2016202437B2/en
Publication of AU2016202437A1 publication Critical patent/AU2016202437A1/en
Application granted granted Critical
Publication of AU2016202437B2 publication Critical patent/AU2016202437B2/en
Assigned to Arrowhead Pharmaceuticals, Inc. reassignment Arrowhead Pharmaceuticals, Inc. Request to Amend Deed and Register Assignors: ARROWHEAD RESEARCH CORPORATION
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2016202437A 2011-09-02 2016-04-18 Organic compositions to treat HSF1-related diseases Active AU2016202437B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016202437A AU2016202437B2 (en) 2011-09-02 2016-04-18 Organic compositions to treat HSF1-related diseases

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161530532P 2011-09-02 2011-09-02
US61/530,532 2011-09-02
US201261598453P 2012-02-14 2012-02-14
US61/598,453 2012-02-14
AU2012303650A AU2012303650B2 (en) 2011-09-02 2012-08-30 Organic compositions to treat HSF1-related diseases
AU2016202437A AU2016202437B2 (en) 2011-09-02 2016-04-18 Organic compositions to treat HSF1-related diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2012303650A Division AU2012303650B2 (en) 2011-09-02 2012-08-30 Organic compositions to treat HSF1-related diseases

Publications (2)

Publication Number Publication Date
AU2016202437A1 true AU2016202437A1 (en) 2016-05-12
AU2016202437B2 AU2016202437B2 (en) 2016-12-01

Family

ID=47143967

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016202437A Active AU2016202437B2 (en) 2011-09-02 2016-04-18 Organic compositions to treat HSF1-related diseases

Country Status (11)

Country Link
US (3) US20160032284A1 (en)
EP (3) EP3098314B1 (en)
JP (2) JP2014525435A (en)
KR (1) KR20140057374A (en)
CN (1) CN103930547A (en)
AU (1) AU2016202437B2 (en)
BR (1) BR112014005103A2 (en)
CA (2) CA2847283C (en)
EA (1) EA201490553A1 (en)
MX (1) MX2014002536A (en)
WO (1) WO2013030778A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
CA2946751A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
ES2937963T3 (en) 2015-07-21 2023-04-03 Modernatx Inc Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EA201891001A1 (en) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. VACCINES ON THE BASIS OF NUCLEIC ACIDS AGAINST WINDSHEAD VIRUS (VZV)
CA3002819A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
MA50335A (en) 2016-12-08 2020-08-19 Modernatx Inc NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA52262A (en) 2017-03-15 2020-02-19 Modernatx Inc BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2021231678A1 (en) * 2020-05-13 2021-11-18 University Of Massachusetts Reducing prominin2-mediated resistance to ferroptotic cell death
WO2022006436A2 (en) * 2020-07-01 2022-01-06 Bioaffinity Technologies, Inc. Compositions and methods for cellular delivery of rna

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696561B1 (en) 1909-07-09 2004-02-24 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7053052B2 (en) 1997-01-21 2006-05-30 Voellmy Richard W Therapies involving mutated heat shock transcription factor
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
EP2363478B1 (en) 1999-04-21 2019-07-24 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
WO2001075164A2 (en) 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
EP1399189A1 (en) 2001-06-11 2004-03-24 Universite De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
WO2003000861A2 (en) 2001-06-22 2003-01-03 The Regents Of The University Of California Eukaryotic genes involved in adult lifespan regulation
JP5170934B2 (en) 2001-08-16 2013-03-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Synthesis and use of reagents for improved DNA lipofection and / or sustained release prodrugs and drug therapy
WO2004002453A1 (en) 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2004029213A2 (en) 2002-09-28 2004-04-08 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP2006507841A (en) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
DE60332277D1 (en) 2002-11-26 2010-06-02 Univ Massachusetts ADMINISTRATION OF SIRNAS
WO2004064731A2 (en) 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
MXPA06002216A (en) 2003-08-28 2006-04-27 Novartis Ag INTERFERING RNA DUPLEX HAVING BLUNT-ENDS AND 3aCO-MODIFICATIONS.
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CN101184839A (en) 2005-04-08 2008-05-21 纳斯泰克制药公司 Rnai therapeutic for respiratory virus infection
US8354384B2 (en) 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
US20090062222A1 (en) * 2005-09-29 2009-03-05 Trustees Of Boston University Methods for Sensitizing Cancer Cells to Inhibitors
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
US7919603B2 (en) 2005-12-19 2011-04-05 New York University Heat shock RNA
US8329888B2 (en) 2006-03-23 2012-12-11 Santaris Pharma A/S Small internally segmented interfering RNA
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2008022035A2 (en) 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7858592B2 (en) 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
WO2008141074A1 (en) 2007-05-10 2008-11-20 Salk Institute For Biological Studies Identification of compounds that protect against amyloid diseases
MY153691A (en) 2007-05-22 2015-03-13 Arcturus Therapeutics Inc Hydroxymethyl substituted rna oligonucleotides and rna complexes
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009103067A2 (en) 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
WO2010135669A1 (en) * 2009-05-22 2010-11-25 Sabiosciences Corporation Arrays and methods for reverse genetic functional analysis
US9072774B2 (en) 2009-10-16 2015-07-07 University Health Network Porphyrin nanovesicles
US8293718B2 (en) * 2009-12-18 2012-10-23 Novartis Ag Organic compositions to treat HSF1-related diseases
KR101733096B1 (en) 2015-09-25 2017-05-24 강건우 Rice cooker for microwave

Similar Documents

Publication Publication Date Title
AU2016202437A1 (en) Organic compositions to treat HSF1-related diseases
EP2729131A4 (en) Topical compositions
HK1206387A1 (en) Organic compositions to treat kras-related diseases kras
EP2706987B8 (en) Pharmaceutical compositions
EP2684167A4 (en) Compositions and methods useful for treating diseases
HK1214949A1 (en) Organic compositions to treat hsf1-related diseases hsf1
WO2012145254A9 (en) Methods of using inhibitors of rorϒt to treat disease
PT2694021E (en) Healing composition for topical application
PT2739276T (en) Antiseptic composition
AU2016202513A1 (en) Composition
HK1214301A1 (en) Organic compositions to treat epas1-related diseases epas1
EP2625353A4 (en) Improvements to fencing
EP2697183B8 (en) Composter
IL221399A (en) Compositions for treating viral diseases
PL2663198T3 (en) Compositions relating to carotenoids
EP2673181A4 (en) Linkage arrangement
AU2011903969A0 (en) Compositions for treating skin conditions
AU2011905349A0 (en) Improvements to apiculture
AU2012903983A0 (en) Method to improve crop yields
AU2011900644A0 (en) Therapeutic Uses of SLIRP
GB201100455D0 (en) Methods relating to treatment
AU2011902775A0 (en) Treatment of radiata pine
AU2011902717A0 (en) Treatment of radiata pine
AU2011900020A0 (en) Processing of organic matter
AU2011905315A0 (en) Reperfusion Treatment